4.5 Review

A psychoneuroimmunological perspective to Emil!Kraepelins dichotomy -: Schizophrenia and major depression as inflammatory CNS disorders

出版社

SPRINGER HEIDELBERG
DOI: 10.1007/s00406-008-2012-3

关键词

psychoneuroimmunology; schizophrenia; major depression; dichotomy dlutamare

向作者/读者索取更多资源

The Kraepelinian classification of psychiatric disorders, in particular the dichotomy of dementia praecox and manic-depressive psychosis is under discussion since a long time. In recent years, not only new research in the fields of psychopathology and clinical outcome, but also findings of biological markers in the areas of neurophysiology, neuroendocrinology, psychoneuroimmunology, genetics, or psychopharmacology show a big overlap between both groups of disorders. This overlap of symptoms and markers of both disorders intensified the discussion and the proposals for new criteria for the classification of psychiatric disorders. By means of findings from the field of psychoneuroimmunology and inflammation it will be shown that different pathological mechanisms in depression and schizophrenia may lead to the same final common pathway of inflammation. These mechanisms include the immunological balance between type-1 and type-2 immune activation which influences the tryptophan-degradating enzyme indoleamine 2,3-dioxygenase (IDO) in the CNS in opposite ways, leading to an altered availability of tryptophan and serotonin, and a disturbance of the kynurenine metabolism with an imbalance in favor of the production of the NMDA-receptor agonist quinolinic acid in depression and of the NMDA-receptor antagonist kynurenic acid in schizophrenia. In both disorders, however, an increased production of prostaglandin E2 and increased expression of cyclo-oxygenase-2 reflect a slight inflammatory process taking place probably in different regions of the CNS. Albeit this common inflammatory pathway-inflammation is a general pathway of the body as answer to a lot of different noxae and pathogens-the Kraepelinian dichotomy is important with respect to pathological mechanisms and therapeutic approaches, not only for further research in understanding the exact pathological mechanisms but also for the development of preventive strategies in high risk individuals and in patients. Opposite pathways regarding the immune activation, the neurotoxic versus neuroprotective kynurenine metabolites and the agonistic versus antagonistic effects on the NMDA receptor and the glutamatergic neurotransmission show despite a possible therapeutic advantage of anti-inflammatory therapy in both disorders that the Kraepelinian dichotomy still has a significant value from a biologic-psychiatric point of view.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Clinical Neurology

Trends in Prevalence of Parkinson's Disease in German General and Neurological Practices from 2010 to 2019

Jens Bohlken, Steffi Riedel-Heller, Antje Kramer, Karel Kostev, Anette Schrag

Summary: There was no increase in the number of patients with Parkinson's disease in Germany from 2010 to 2019, but there was an increase in the proportion of elderly patients and a decrease in the proportion of female patients.

FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE (2023)

Article Geriatrics & Gerontology

The Validity of Health-Related Quality of Life Instruments in Patients With Late-Stage Parkinson's Disease

Mouhammed Ramadhan, Anette Schrag

Summary: This study aimed to examine the validity of health-related quality of life (Hr-QoL) measures in patients with late-stage Parkinson's disease (PD). The results showed that the PDQ-8 and EQ-5D-3 L have adequate validity in late-stage PD without dementia, but in those with PD and dementia, the EQ-5D-3 L may be preferable to the DEMQOL-Proxy.

JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY (2023)

Article Clinical Neurology

Cognitive impairment in REM-sleep behaviour disorder and individuals at risk of Parkinson's disease

A. V. Nagy, G. Leschziner, S. H. Eriksson, A. Lees, A. J. Noyce, A. Schrag

Summary: Cognitive impairment is more prevalent in individuals at higher risk of PD, especially those with REM-sleep behaviour disorder.

PARKINSONISM & RELATED DISORDERS (2023)

Article Clinical Neurology

A Comparison Between Early Presentation of Dementia with Lewy Bodies, Alzheimer's Disease, and Parkinson's Disease: Evidence from Routine Primary Care and UK Biobank Data

Thomas Nedelec, Baptiste Couvy-Duchesne, Aube Darves-Bornoz, Raphael Couronne, Fleur Monnet, Laurene Gantzer, Beranger Lekens, Yeda Wu, Nicolas Villain, Anette Schrag, Stanley Durrleman, Jean-Christophe Corvol

Summary: This study compared the prediagnostic clinical characteristics of individuals with DLB, PD, and AD, and found that falls, psychiatric symptoms, and autonomic dysfunctions were more strongly associated with DLB than PD and AD in the 5 years preceding the first neurodegenerative diagnosis. Additionally, the use of statins was less common in PD patients but more common in DLB and AD patients.

ANNALS OF NEUROLOGY (2023)

Letter Clinical Neurology

Confusion of evidence-based reviews and guidelines

Gunther Deuschl, Angelo Antonini, Joao Costa, Katarzyna Smilowska, Daniela Berg, Jean-Christophe Corvol, Giovanni Fabbrini, Joaquim Ferreira, Tom Foltynie, Pablo Mir, Anette Schrag, Klaus Seppi, Pille Taba, Evzen Ruzicka, Marianna Selikhova, Nicholas Henschke, Gemma Villanueva, Elena Moro

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Development of anxiety in early Parkinson's disease: A clinical and biomarker study

Hanyuying Wang, Yibo Zhao, Anette Schrag

Summary: This study aimed to identify the clinical factors and biomarkers associated with the development of anxiety in newly diagnosed Parkinson's disease (PD) patients, as well as to predict the risk factors for increasing anxiety levels over time. The results showed that anxiety development is related to non-dopaminergic or extrastriatal pathology rather than a dopaminergic deficit in the basal ganglia. Early dysexecutive function predicts the development of anxiety, and an increase in anxiety levels correlates most strongly with global cognitive decline.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

The Pain in Dystonia Scale (PIDS)-Development and Validation in Cervical Dystonia

Veronica Bruno, Beatrice Achen, Francesca Morgante, Roberto Erro, Susan H. Fox, Mark J. Edwards, Anette Schrag, Maria Stamelou, Silke Appel-Cresswell, Giovanni Defazio, K. Ray Chaudhuri, Sarah Pirio Richardson, Hyder A. Jinnah, Davide Martino

Summary: This study developed and validated a new rating instrument, Pain in Dystonia Scale (PIDS), to assess pain in adult-onset idiopathic dystonia (AOID). The PIDS evaluates pain severity, functional impact, and external modulating factors. It demonstrated high-level psychometric properties in patients with cervical dystonia (CD).

MOVEMENT DISORDERS (2023)

Letter Clinical Neurology

Summing MDS-UPDRS Parts 1+2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice

Haotian Zou, Christopher G. Goetz, Glenn T. Stebbins, Anette Schrag, Tiago A. Mestre, Sheng Luo

MOVEMENT DISORDERS (2023)

Editorial Material Medicine, General & Internal

Focused Ultrasound Ablation of the Globus Pallidus Internus for Parkinson's Disease

Anette Schrag

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Article Psychiatry

Polygenic risk score-based phenome-wide association study identifies novel associations for Tourette syndrome

Pritesh Jain, Tyne Miller-Fleming, Apostolia R. Topaloudi, Dongmei K. Yu, Petros Drineas, Marianthi Georgitsi, Zhiyu Yang, Renata Rizzo, Kirsten R. Mueller-Vahl, Zeynep A. Tumer, Nanette Mol Debes, Andreas S. Hartmann, Christel E. Depienne, Yulia S. Worbe, Pablo Mir, Danielle C. Cath, Dorret Boomsma, Veit Roessner, Tomasz Wolanczyk, Piotr Janik, Natalia Szejko, Cezary Zekanowski, Csaba Barta, Zsofia Nemoda, Zsanett Tarnok, Joseph D. Buxbaum, Dorothy Grice, Jeffrey Glennon, Hreinn Stefansson, Bastian Hengerer, Noa Benaroya-Milshtein, Francesco Cardona, Tammy Hedderly, Isobel Heyman, Chaim Huyser, Astrid Morer, Norbert Mueller, Alexander Munchau, Kerstin J. Plessen, Cesare Porcelli, Susanne Walitza, Anette Schrag, Davide Martino, Andrea Dietrich, Carol A. Mathews, Jeremiah M. Scharf, Pieter J. Hoekstra, Lea K. Davis, Peristera Paschou

TRANSLATIONAL PSYCHIATRY (2023)

Article Neurosciences

Association between Antiepileptic Drugs and Incident Parkinson's Disease among Patients Followed in German Primary Care Practices

Karel Kostev, Corinna Doege, Louis Jacob, Lee Smith, Ai Koyanagi, Celina Gollop, Anette Schrag

Summary: This study analyzed whether prescriptions of antiepileptic drugs (AEDs) are significantly associated with an increased incidence of Parkinson's disease (PD) in the German population. The results showed that diagnoses of epilepsy, restless legs syndrome, and neuropathy, as well as the prescription of AEDs including sodium valproate, gabapentin, and pregabalin, were significantly associated with an increased incidence of PD. Further studies are needed to confirm the present results.

BRAIN SCIENCES (2023)

Article Neurosciences

The experience of Anxiety for people with Parkinson's disease

Emma. K. Blundell, Laura. E. Grover, Joshua Stott, Anette Schrag

Summary: Anxiety is a common and important non-motor symptom of Parkinson's disease (PD), yet it is poorly understood, underdiagnosed, and undertreated. This study aimed to explore the experience of anxiety for people with Parkinson's (PWP) through interviews and thematic analysis. The findings revealed the complexity of anxiety, its impact on daily life, and the connection to PD. The study highlights the need for better recognition and treatment of anxiety in PWP.

NPJ PARKINSONS DISEASE (2023)

Article Clinical Neurology

Falling incidence of Parkinson's disease in Germany

Lotte Dammertz, Anette Schrag, Jens Bohlken, Joachim Heuer, Claudia Kohring, Julia Schorlemmer, Manas K. Akmatov, Joerg Baetzing, Jakob Holstiege

Summary: This study aimed to describe the trends and regional differences in the incidence of IPD diagnosed in older people in Germany. The data were collected from nationwide outpatient claims and drug prescription data. The results showed a decline in the incidence of IPD from 2013 to 2019 in Germany.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Article Neurosciences

Outcome Measures for Disease-Modifying Trials in Parkinson's Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative

Cristina Gonzalez-Robles, Rimona S. Weil, Daniel van Wamelen, Michele Bartlett, Matthew Burnell, Caroline S. Clarke, Michele T. Hu, Brook Huxford, Ashwani Jha, Christian Lambert, Michael Lawton, Georgia Mills, Alastair Noyce, Paola Piccini, Kuhan Pushparatnam, Lynn Rochester, Carroll Siu, Caroline H. Williams-Gray, Marie-Louise Zeissler, Henrik Zetterberg, Camille B. Carroll, Thomas Foltynie, Anette Schrag

Summary: This study aims to provide an inventory of outcome measures (OM) for disease-modifying trials in Parkinson's disease and a framework for future selection of OM. An extensive inventory of OM was created based on evidence evaluation. Patient and public involvement emphasized the need for OM reflecting their disease experience and applicable to diverse populations and disease stages.

JOURNAL OF PARKINSONS DISEASE (2023)

Article Clinical Neurology

Delivering Optimal Care to People with Cognitive Impairment in Parkinson's Disease: A Qualitative Study of Patient, Caregiver, and Professional Perspectives

Jennifer S. Pigott, Nathan Davies, Elizabeth Chesterman, Joy Read, Danielle Nimmons, Kate Walters, Megan Armstrong, Anette Schrag

Summary: Cognitive impairment in Parkinson's disease (PD) poses complex challenges for clinical management and healthcare interactions. The support needs of both PD patients and caregivers are often unmet, with inconsistent diagnostic pathways and poor awareness of cognitive impairment in PD. Clinicians should adapt their approach and provide tailored information and support, while services should be more streamlined and collaborative. Wider awareness and understanding of this condition and its differences from other types of dementia are needed.

PARKINSONS DISEASE (2023)

暂无数据